<DOC>
	<DOCNO>NCT00006017</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know regimen rebeccamycin analogue effective treat non-small cell lung cancer . PURPOSE : Randomized phase II trial compare effectiveness two rebeccamycin analogue regimen treat patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Two Rebeccamycin Analogue Regimens Treating Patients With Advanced Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy , term response rate , patient advance recurrent non-small cell lung cancer treat rebeccamycin analogue via 1 infusion v 5 daily infusion every 3 week . - Compare response duration patient treat regimen . - Compare toxicity profile two regimen patient . OUTLINE : This randomize , multicenter study . Patients stratify accord performance status ( 0 1 v 2 ) participate center . Patients randomize one two treatment arm . - Arm I : Patients receive rebeccamycin analogue IV 1 hour day 1 . - Arm II : Patients receive rebeccamycin analogue IV 1 hour day 1-5 . Treatment arm repeat every 3 week 6-8 course absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 36-64 patient ( 18-32 per arm ) accrue study rate 3-4 patient per month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIB ( pleural effusion ) , IV , recurrent nonsmall cell lung cancer failure 1 prior chemotherapy regimen Measurable disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST ALT less 2 time normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent combination antiretroviral therapy HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>